C.J. Peters, M.D.

C.J. Peters, M.D.

John Sealy Distinguished University Chair in Tropical and Emerging Virology;
Professor, Departments of Microbiology & Immunology and Pathology;
Director for Biodefense, Center for Biodefense & Emerging Infectious Diseases

University of Texas Medical Branch
301 University Boulevard
1.104B Keiller Building
Galveston, TX 77555-0609

Office: (409) 772-0090
Fax: (409) 747-0762
cjpeters@utmb.edu

« Back

C.J. Peters, M.D.

Professional Education

Degree Institution Field of Study Graduation Year
M.D. Johns Hopkins University, Baltimore, Maryland Medicine 1966
A.B. Rice University, Houston, Texas Chemistry
(summa cum laude)
1962

Honors

  Alpha Omega Alpha
  Phi Beta Kappa
  Phi Lambda Upsilon
  Sigma Xi
1981 Surgeon General's Award
1986 Army Science Conference Award
1989 "A" Research Proficiency Designator Award, U.S. Army
  Army Achievement Award
  Army Commendation Medal
1994 Secretary’s Award, Health and Human Services (Hantavirus investigation)
1994 Enders Lecture, Infectious Disease Society of America
1996 Secretary’s Award, Health and Human Services (Ebola investigation)
2000 Secretary’s Award, Health and Human Services (Nipah investigation)
2006 Pan American Society for Clinical Virology, Clinical Virology Award

Professional Affiliations

  • Board Certification: American Board of Internal Medicine
  • Medical License: State of Maryland

Research Interests

Current topics of research in the lab are Rift Valley fever vaccines and pathogenesis of SARS. Also, innate resistance to SARS, Rift Valley fever virus, arenaviruses, Thogoto-like viruses.

Selected Publications

  1. Peters CJ, Kuehne RW, Mercado R, Le Bow RH, Spertzel RO, Webb PA: Hemorrhagic fever in Cochabamba, Bolivia, 1971. Am J Epidemiol 99:425-433, 1974.
  2. Kark JD, Aynor Y, Peters CJ: A Rift Valley fever vaccine trial. I. Side effects and serologic response over a six-month follow-up. Am J Epidemiol 116:808-820, 1982.
  3. Peters CJ, Slone TW: Inbred rat strains mimic the disparate human response to Rift Valley fever. J Med Virol 10:45-54, 1982.
  4. Jahrling PB, Peters CJ, Stephen EL: Enhanced treatment of Lassa fever by immune plasma combined with ribavirin in cynomolgus monkeys. J Infect Dis 149:420-427, 1984.
  5. Caplen HC, Peters CJ, Bishop DHL: Mutagen directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 66:2271-2277, 1985.
  6. Niklasson B, Peters CJ, Bengtsson E, Norrby E: Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans. Vaccine 3:123-127, 1985.
  7. McKee KT, Mahlandt BG, Maiztegui JI, Eddy GA, Peters CJ: Experimental Argentine hemorrhagic fever in rhesus macaques: viral strain-dependent clinical response. J Infect Dis 152:218-221, 1985.
  8. Peters CJ, Reynolds JA, Slone TW, Jones DE, Stephen EL: Prophylaxis of Rift Valley fever with antiviral drugs, immune serum, an interferon inducer, and a macrophage activator. Antiviral Res 6:285-297, 1986.
  9. Kenyon RH, Green DE, Eddy GA, Peters CJ: Treatment of Junin virus-infected guinea pigs with immune serum: Development of late neurological disease. J Med Virol 20:207-218, 1986.
  10. Liu CT, Jahrling PB, Peters CJ: Evidence for the involvement of sulfidopeptide leukotrienes in the pathogenesis of Pichinde virus infection in strain 13 guinea pigs. Prostaglandins Leukotrienes Med 24:129-138, 1986.
  11. Morrill JC, Jennings GB, Caplen H, Turell MJ, Johnson AJ, Peters CJ: Pathogenecity and immunogenicity of a mutagen-attenuated Rift Valley fever virus immunogen in pregnant ewes. Am J Vet Res 48:1042-1047, 1987.
  12. Peters CJ, Jahrling PB, Liu CT, Kenyon RH, McKee KT Jr, Barrera Oro JG: Experimental studies of arenaviral hemorrhagic fevers. In Current Topics in Microbiology and Immunology, Vol. 134, Arenaviruses: Epidemiology and Immunotherapy, pp. 5-68 (M.B. Oldstone, ed.). Springer-Verlag, Heidelberg, 1987.
  13. Anderson GW Jr, Peters CJ: Viral determinants of virulence for Rift Valley fever (RVF) in rats. Microb Pathog 5:241-250, 1988.
  14. Anderson GW Jr, Rosebrock JA, Johnson AJ, Jennings GB, Peters CJ: Infection of inbred rat strains with Rift Valley fever virus: development of a congenic resistant strain and observations on age-dependence of resistance. Am J Trop Med Hyg 44:475-480, 1991.
  15. Nichol ST, Spiropoulou CF, Morzunov S, Rollin PE, Ksiazek TG, Feldmann H, Sanchez A, Childs J, Zaki S, Peters CJ: Genetic identification of a hantavirus associated with an outbreak of acute respiratory illness. Science 262:914-17, 1993.
  16. Zaki SR, Greer PW, Coffield LM, Goldsmith CS, Nolte KB, Foucar K, Feddersen RM, Zumwalt RE, Miller GL, Khan AS, Rollin PE, Ksiazek TG, Nichol ST, Mahy BWJ, Peters CJ: Hantavirus pulmonary syndrome: pathogenesis of an emerging infectious disease. Am J Pathol 146:552-579, 1995.
  17. Wells RM, Sosa Estani S, Yadon ZE, Enria D, Padula P, Pini N, Mills JN, Peters CJ, Segura EL, and the Hantavirus Pulmonary Syndrome Study Group for Patagonia: An unusual hantavirus outbreak in southern Argentina: Person-to-person transmission? Emerg Infect Dis 3:171-174, 1997.
  18. Maiztegui JI, McKee KT, Barrera Oro JG, Harrison LH, Gibbs PH, Feuillade MR, Enria DA, Briggiler AM, Levis SC, Ambrosio AM, Halsey NA, Peters CJ, the AHF Study Group: Protective efficacy of a live attenuated vaccine against Argentine hemorrhagic fever. J Infect Dis 177:277-283, 1998.
  19. Peters CJ and LeDuc JW: An introduction to Ebola: the virus and the disease. J Infect Dis 179 (Suppl 1):ix-xvi, 1999.
  20. Bausch DG, Demby AH, Coulibaly M, Kanu J, Goba A, Bah A, Conde N, Wurtzel HL, Cavallaro KF, Lloyd E, Baldet FB, Cisse SD, Fofona D, Savane IK, Tolno RT, Mahy B, Wagoner KD, Ksiazek TG, Peters CJ, Rollin PE: Lassa Fever in Guinea: I. Epidemiology of human disease and clinical observations. Vector Borne Zoonotic Dis 1:269-281, 2001.
  21. Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P, Muchiri E, Dunster L, Henderson A, Khan AS, Swanepoel R, Bonmarin I, Martin L, Mann P, Smoak B, Ryan M, Ksiazek TG, Arthur RR, Ndikuyeze A, Agata NN, Peters CJ: The WHO Hemorrhagic Fever Task Force: An outbreak of Rift Valley fever in northeastern Kenya, 1997-98. Emerg Infect Dis 8:138-144, 2002.
  22. Yates TL, Mills JN, Parmenter CA, Ksiazek TG, Parmenter RR, Vande Castle JR, Calisher CH, Nichol ST, Abbott KD, Yound JC, Morrision ML, Beaty BJ, Dunnun JL, Baker RJ, Salazar-Bravo J, Peters CJ: The ecology and evolutionary history of an emergent disease: hantavirus pulmonary syndrome. BioScience 52:989, 2002.
  23. Ikegami T, Won S, Peters CJ, Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 80:2933-2940, 2006.
  24. Mossel EC, Sainz B Jr, Garry RF, Peters CJ. Synergistic inhibition of SARS-coronavirus replication by type I and type II IFN. Adv Exp Med Biol 581:503-506, 2006.
  25. Yoshikawa T, Hill T, Peters CJ, Tseng CT. Severe Acute Respiratory Syndrome-Coronavirus (SARS-CoV)-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. J Virol. 83(7):3039-3048, 2009.

NIH Biosketch